AstraZeneca, Biovail enter into agreement for Zoladex

Share this article:
AstraZeneca and Biovail have entered into an agreement in which Biovail's specialty sales force will promote AstraZeneca's Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. Biovail's 85-member specialty sales force currently promotes Zovirax cream and ointment to specialists and selected primary-care physicians in the US. 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.